Staff Reports
President Donald Trump’s team just sent a clear message to Berlin: don’t expect the United States to quietly finance the world’s drug research while other wealthy nations keep cutting prices for themselves. A recent meeting in Washington brought U.S. Trade Representative Jamieson Greer and HHS chief counselor Chris Klomp face-to-face with German Ambassador Jens Hanefeld to press Germany over a new drug-pricing package. The message was blunt — Section 301 trade tools, including tariffs, are on the table if Germany forces down prices and forces Americans to pick up the bill.
What happened in Washington: Germany drug pricing meets Section 301
The German cabinet approved a sweeping health reform package that tightens price controls, raises mandatory rebates to sickness funds, and adds new rules on digital health apps. It’s meant to shore up Germany’s public insurance finances. But the U.S. delegation made clear this is not just a domestic German matter. USTR Jamieson Greer and HHS’s Chris Klomp warned Ambassador Jens Hanefeld that aggressive price curbs in a big market like Germany will invite a U.S. trade response. Yes, they discussed Section 301 — the same tool used to enforce trade fairness. That’s a big step from polite diplomacy to real leverage over Germany drug pricing.
Why Germany’s reforms matter for American patients and pharma
Here’s the plain fact: U.S. companies develop a huge share of the world’s new medicines. That research costs billions and takes years. When big markets like Germany push prices down with heavy-handed rules, companies make less money there and raise prices where they can — often in the United States. That is what Trump calls “global freeloading.” Germany’s AMNOG-style bargaining and the new rebate measures will squeeze pharma revenue further. Chancellor Friedrich Merz calls the bill “historic,” but history will also remember which countries expect Americans to pay more for their innovation.
Trade pressure is the right tool — with smart guardrails
Let’s be honest: trade tools like Section 301 are blunt. They can prod fairer behavior, but they can also lead companies to delay or withhold launches in Europe. That risk exists. Still, the Trump administration is right to put its cards on the table. If Berlin wants cheap drugs at the cost of American jobs and American research, Washington should respond. Use negotiation, not naïve lecturing. Tie market access and cooperation to fair pricing practices. And if tariffs become necessary, make them targeted and temporary — aimed at restoring balance, not sparking a trade war over pocket change.
Bottom line: Protect American innovation, and make others pay their share
Germany can reform its health system all it likes. But it should not do so by freeloading on U.S. taxpayers and investors who bankroll the next miracle drug. President Donald Trump’s push to use trade and diplomatic pressure is a necessary wake-up call to allies who think U.S. innovation is a free buffet. The message to Berlin should be simple: change your pricing scheme, negotiate fairly, or face consequences. That’s not protectionism for its own sake — it’s common sense protection of American patients and American ingenuity.
